Join to View Full Profile
530 East 74th StreetNew York, NY 10021
Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of SydneyMPH, 2012 - 2014
- University of New South Wales Faculty of MedicineClass of 2006
Certifications & Licensure
- NY State Medical License 2015 - 2025
Clinical Trials
- Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
- DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer Start of enrollment: 2018 May 21
- A First-in-human Study Using BDC-1001 As a Single Agent and in Combination with Nivolumab in Advanced HER2-Expressing Solid Tumors Start of enrollment: 2020 Feb 24
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAn ultrasensitive method for detection of cell-free RNA.Monica C Nesselbush, Bogdan A Luca, Young-Jun Jeon, Isabel Jabara, Catherine B Meador
Nature. 2025-04-16 - Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Dazhi Liu, Justin Jee, Alexander Drilon, Andreas M Heilmann, Justin M Allen
Cancer Research Communications. 2025-04-01 - Cell-Free Circulating Tumor DNA for NonInvasive Molecular Profiling Among Patients Undergoing Definitive Chemoradiation for Locally Advanced Lung Cancer.Emily S Lebow, Jordan Eichholz, Lillian Boe, Zhigang Zhang, Leah B Kratochvil
Advances in Radiation Oncology. 2025-04-01
Lectures
- Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.2019 ASCO Annual Meeting - 6/1/2019
- A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Authored Content
- We Need a Global System for Testing and Approving Cancer TreatmentsOctober 2022
Press Mentions
- Potential New Treatment for KRAS-GI2D Lung Cancer Reported in First-of-Its-Kind Clinical TrialApril 27th, 2025
- AstraZeneca Names a MSK Leader to Global Cancer PostNovember 25th, 2024
- MSK Research Highlights, May 18, 2023May 18th, 2023
- Join now to see all
Grant Support
- HER2-mediated delivery of cytotoxic agents in solid tumorsSLOAN-KETTERING INST CAN RESEARCH2021–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: